LABORATORY REF. NO.

87923/A
Mahavir Hospital and Research Centre

Mahavir Hospital and Research Centre

MONTHLY CLINICAL CHEMISTRY

CYCLE 16 SAMPLE 10

Explanation of codes used in this report

R - Results removed due to reconstitution error

N - No result returned
C - Result corrected

Authorised by: Stephen Doherty, RIQAS Manager Issue No: 1 Issue Date: 30/10/2019

Randox Laboratories Limited

55 Diamond Road

ABC
CRUMLIN BT29 4QY
Tel: +44 (0)28 9445 4399
Fax: +44 (0)28 9445 4398
Email: mail@riqas.com Page 1 A
MONTHLY CLINICAL CHEMISTRY LABORATORY REF. NO. 87923/A CYCLE 16 SAMPLE 10 28/10/2019
Mean for Comparison

Albumin, g/dl

I 4.045

I 2.986

I 4.100

I 4.042

I 4.058

I 4.169

I 2.890

I 3.960

I 5.194

I 4.030

I 4.082

I 2.826

I 4.006

I 2.285

I 5.077

I 4.072

I 3.052

I 4.026

I 4.044

I 3.128
>+3

N Mean CV% Um SDPA Exc.

+2

All Methods 4426 3.111 5.6 0.00 0.18 267

Bromocresol Green 3679 3.132 5.4 0.00 0.18 260 +11

Standard Deviation
Thermo Konelab 20/30/60/Indiko 33 3.128 4.2 0.03 0.18 3
0

-1
Your Result 3.500 SDI 2.10
RMSDI 0.37
-2

Mean for Comparison 3.128 TS 39

RMTS 59 <-3

N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10

%DEV 11.9 Sample Number

RM%DEV 2.2 TDPA = 9.3%

120

110

100

Acceptable limits derived from Biological Variation 4.07 % 90

Acceptable limits of performance for RIQAS 9.30 % 80

70

Target Score
SDI in bottom 5% of peer group 60

TS & %DEV outside limits 50

40

30

20

10

N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10

Sample Number

600 >= 20

15
500
Number of Laboratories

10

400
5
% Deviation

0
300

-5

200
-10

100 -15

<= -20

0 N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10
Sample Number
< 2.65 2.78 2.91 3.04 3.17 3.30 3.43 3.56 >
g/dl
>= 20

15
Method N Mean CV% Um
10
Bromocresol Green 3679 3.132 5.4 0.00
Bromocresol Purple 476 3.006 4.1 0.01
5
Ortho Vitros MicroSlide Systems 155 3.012 3.3 0.01
% Deviation

Agappe - Bromocresol Green 22 3.314 3.6 0.03

Turbidimetric Assays 25 2.893 8.3 0.06 0

Other Dry Chemistry 11 3.418 6.8 0.09

Nephelometric Assays 5 3.282 10.5 0.19 -5
Vitros DT60/DT60 II/DTSC II 2 2.900 4.9 0.12
Electrophoresis 2 3.045 7.2 0.19
-10

-15

<= -20

0 1 2 3 4 5 6

Concentration

Issue No: 1 Issue Date: 30/10/2019 Page 2

A ABC
MONTHLY CLINICAL CHEMISTRY LABORATORY REF. NO. 87923/A CYCLE 16 SAMPLE 10 28/10/2019
Mean for Comparison

I 155.146

I 295.319

I 162.229

I 153.846

I 192.367

I 181.041

I 299.763

I 164.841

I 327.884

I 193.977

I 162.457

I 301.726

I 165.143

I 289.452

I 154.043

I 310.313

I 171.104

I 167.190

I 294.930
I 13.792
Alkaline Phosphatase, U/l @ 37°C
>+3

N Mean CV% Um SDPA Exc.

+2

All Methods 3758 296.365 16.6 1.00 30.45 274

AMP optimised to IFCC 1474 310.584 11.9 1.20 31.91 77 +11

Standard Deviation
Thermo Konelab 20/30/60/Indiko 23 294.930 4.8 3.69 30.30 6
0

-1
Your Result 376.000 SDI 2.68
RMSDI 1.34
-2

Mean for Comparison 294.930 TS 29

RMTS 29 <-3

N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10

%DEV 27.5 Sample Number

RM%DEV 14.1 TDPA = 16.9%

120

110

100

Acceptable limits derived from Biological Variation 12.04 % 90

Acceptable limits of performance for RIQAS 16.90 % 80

70

Target Score
SDI in bottom 5% of peer group 60

TS & %DEV outside limits 50

40

30

20

10

N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10

Sample Number

700
>= 60

600
40
Number of Laboratories

500
20

400
% Deviation

300

-20

200

-40

100

<= -60

0 N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10
Sample Number
< 167.19 204.09 241.00 277.91 314.81 351.72 388.63 425.53 >
U/l
>= 60

Method N Mean CV% Um 40

AMP optimised to IFCC 1474 310.584 11.9 1.20

Roche AMP buffer IFCC 894 250.297 3.8 0.39 20

Diethanolamine buffer, DEA 466 411.059 13.4 3.20

% Deviation

Siemens/Dade Dimension AMP buffer 199 279.126 3.2 0.80

Ortho Vitros MicroSlide Systems 164 240.528 6.6 1.55 0

AMP non-optimised 161 313.132 7.5 2.31

Beckman AMP (Calibrator) 139 362.939 4.4 1.70
Colorimetric 89 283.758 11.9 4.47 -20

Other AMP kits 83 295.819 4.9 2.01

Agappe - DGKC-SCE 22 355.852 12.0 11.39
Other Dry Chemistry 13 331.375 13.0 14.94 -40

AMP optimised to NVKC/SFBC 12 310.467 11.7 13.07

Beckman AMP (Extinction Coeff) 10 343.995 6.7 9.12
Tris/carbonate buffer 5 295.020 11.3 18.69 <= -60

Fuji Dri-Chem JSCC 3 1044.333 9.8 73.84 0 50 100 150 200 250 300
Vitros DT60/DT60 II/DTSC II 3 224.667 10.4 16.85
Concentration
AMPD optimised to JSCC 3 297.333 9.7 20.87

Issue No: 1 Issue Date: 30/10/2019 Page 3

A ABC
MONTHLY CLINICAL CHEMISTRY LABORATORY REF. NO. 87923/A CYCLE 16 SAMPLE 10 28/10/2019
Mean for Comparison

I 158.316

I 157.833

I 149.995

I 153.344

I 137.405

I 157.103

I 159.256
I 40.774

I 39.515

I 38.108

I 43.787

I 44.827

I 44.117

I 43.512

I 35.623

I 45.465

I 12.441

I 34.703

I 38.735

I 40.456
ALT (GPT), U/l @ 37°C
>+3

N Mean CV% Um SDPA Exc.

+2

All Methods 5390 149.122 6.8 0.17 13.15 475

Tris buffer without P5P 4170 147.208 6.7 0.19 12.98 394 +11

Standard Deviation
Thermo Konelab 20/30/60/Indiko 36 159.256 5.2 1.74 14.04 3
0

-1
Your Result 165.000 SDI 0.41
RMSDI 0.43
-2

Mean for Comparison 159.256 TS 110

RMTS 90 <-3

N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10

%DEV 3.6 Sample Number

RM%DEV 3.8 TDPA = 14.5%

120

110

100

Acceptable limits derived from Biological Variation 27.48 % 90

Acceptable limits of performance for RIQAS 14.50 % 80

70

Target Score
60

50

40

30

20

10

N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10

Sample Number

700
>= 20

600 15
Number of Laboratories

10
500

5
% Deviation

400
0

300
-5

200 -10

-15
100

<= -20

0 N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10
Sample Number
< 122.57 130.16 137.74 145.33 152.91 160.49 168.08 175.66 >
U/l
>= 20

15
Method N Mean CV% Um
10
Tris buffer without P5P 4170 147.208 6.7 0.19
Tris buffer with P5P 346 157.515 5.1 0.54
5
Beckman Mod. IFCC Ref. without P5P 318 152.050 3.3 0.36
% Deviation

Siemens/Dade standard nonIFCC correlated 158 162.361 3.0 0.48

Ortho Vitros MicroSlide Systems 133 156.993 4.2 0.72 0

Ortho Vitros MicroSlide visible 37 156.393 3.8 1.23

Agappe - IFCC 32 158.473 6.0 2.11 -5
Colorimetric 31 145.798 6.0 1.96
Phosphate buffer, DGKC 27 151.085 7.6 2.75
-10
Other Dry Chemistry 22 154.773 5.7 2.35
Tris buffer, SCE 23 144.037 7.2 2.72
Beckman IFCC Ref. with P5P 19 152.943 4.3 1.90 -15

Tris buffer with P5P, NVKC 15 145.000 3.5 1.62

Beckman (Extinction Coefficient) 7 148.657 7.2 5.07 <= -20

Vitros DT60/DT60 II/DTSC II 2 157.500 0.4 0.62 0 20 40 60 80 100 120 140 160

Concentration

Issue No: 1 Issue Date: 30/10/2019 Page 4

A ABC
MONTHLY CLINICAL CHEMISTRY LABORATORY REF. NO. 87923/A CYCLE 16 SAMPLE 10 28/10/2019
Mean for Comparison

I 301.500

I 322.714

I 682.425

I 328.769

I 672.409

I 337.727

I 310.508
I 86.533

I 91.220

I 91.030

I 97.029

I 98.178

I 94.675

I 94.511

I 97.380

I 90.682

I 20.500

I 97.777

I 98.364

I 94.300
Amylase, Total, U/l @ 37°C
>+3

N Mean CV% Um SDPA Exc.

+2

All Methods 3576 290.095 8.9 0.54 26.28 353

Other 2-chloro-pNPG3 948 289.607 9.1 1.07 26.23 97 +11

Standard Deviation
Thermo Konelab 20/30/60/Indiko 12 310.508 12.4 13.91 31.38a 0
0

-1
Your Result 234.000 SDI -2.44
RMSDI -2.24
-2

Mean for Comparison 310.508 TS 28

RMTS 62 <-3

N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10

%DEV -24.6 Sample Number

RM%DEV -21.2 TDPA = 14.9%

120

110

100

Acceptable limits derived from Biological Variation 14.6 % 90

Acceptable limits of performance for RIQAS 14.90 % 80

70

Target Score
SDI in bottom 5% of peer group 60

TS & %DEV outside limits 50

40

30

20

10

N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10

Sample Number

500 >= 60

40

400
Number of Laboratories

20

300
% Deviation

200
-20

100 -40

<= -60

0 N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10
Sample Number
< 222.67 241.93 261.19 280.46 299.72 318.99 338.25 357.51 >
U/l
>= 60

Method N Mean CV% Um 40

Other 2-chloro-pNPG3 948 289.607 9.1 1.07

Roche liquid stable pNPG7 655 271.136 2.4 0.32 20

Beckman Olympus blocked pNPG7 294 291.810 3.6 0.76

% Deviation

Siemens/Dade Behring 2-chloro-pNPG3 250 330.352 2.3 0.61

Other - blocked pNPG7 143 288.583 7.7 2.33 0

Ortho Vitros MicroSlide Systems 126 186.195 3.4 0.71

Beckman CNPG3 (Master Cal) 121 285.173 3.2 1.03
Abbott Architect cal factor 3431 116 311.842 3.8 1.36 -20

Randox Liquid Ethylidene pNPG7 99 297.739 5.9 2.19

Bayer - blocked pNPG7 84 290.694 3.3 1.30
Other non blocked pNPG7 73 281.172 6.8 2.82 -40

Other 2-chloro-pNP-linked sub. 70 297.717 7.8 3.49

Beckman Synchron AMY7 69 293.591 4.0 1.76
Roche Integra 2-chloro-pNPG7 65 275.387 3.3 1.41 <= -60

Wiener Amilokit (AU/dl) 56 214.671 22.9 8.22 10 110 210 310 410 510 610
Abbott Architect cal factor 3806 50 327.552 5.9 3.44
Concentration
pNP Maltotrioside substrates 39 304.746 8.3 5.07
I.L. 2-chloro-pNPG3 36 297.186 5.9 3.68

ABC
Other Dry Chemistry 30 273.437 11.9 7.43
Other Roche 2-chloro-pNPG7 29 273.054 2.6 1.67
Randox Lyo. Ethylidene pNPG7 26 296.523 3.3 2.43

Issue No: 1 Issue Date: 30/10/2019 Page 5

A
MONTHLY CLINICAL CHEMISTRY LABORATORY REF. NO. 87923/A CYCLE 16 SAMPLE 10 28/10/2019
Mean for Comparison

I 159.303

I 167.414

I 208.378

I 164.419

I 192.397

I 169.865

I 164.078
I 38.103

I 37.853

I 41.303

I 44.039

I 39.280

I 41.853

I 44.403

I 36.727

I 42.124

I 11.565

I 35.053

I 42.706

I 38.769
AST (GOT), U/l @ 37°C
>+3

N Mean CV% Um SDPA Exc.

+2

All Methods 5245 150.659 8.3 0.22 12.64 576

Tris buffer without P5P 4205 148.153 6.0 0.17 12.43 391 +11

Standard Deviation
Thermo Konelab 20/30/60/Indiko 40 164.078 6.2 2.01 13.77 3
0

-1
Your Result 199.000 SDI 2.54
RMSDI 2.34
-2

Mean for Comparison 164.078 TS 31

RMTS 53 <-3

N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10

%DEV 21.3 Sample Number

RM%DEV 20.0 TDPA = 13.8%

120

110

100

Acceptable limits derived from Biological Variation 16.69 % 90

Acceptable limits of performance for RIQAS 13.80 % 80

70

Target Score
SDI in bottom 5% of peer group 60

TS & %DEV outside limits 50

40

30

20

10

N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10

Sample Number
1000

>= 60

800
40
Number of Laboratories

20
600
% Deviation

400

-20

200 -40

<= -60

0 N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10
Sample Number
< 117.68 127.10 136.52 145.94 155.36 164.78 174.20 183.62 >
U/l
>= 60

Method N Mean CV% Um 40

Tris buffer without P5P 4205 148.153 6.0 0.17

Beckman Mod. IFCC Ref. without P5P 329 155.680 3.3 0.36 20

Tris buffer with P5P 263 189.954 5.9 0.86

% Deviation

Ortho Vitros MicroSlide visible 175 193.342 3.7 0.67

Siemens/Dade standard non IFCC corr. 159 187.745 4.0 0.74 0

Agappe - IFCC 35 159.775 8.0 2.70

Colorimetric 30 147.901 4.3 1.45
Phosphate buffer, DGKC 27 151.985 4.6 1.67 -20

Other Dry Chemistry 24 154.583 11.6 4.58

Tris buffer, SCE 21 145.831 4.9 1.96
Tris buffer with P5P, NVKC 17 146.312 3.1 1.36 -40

Beckman IFCC Ref. with P5P 12 181.742 12.2 7.97

Beckman (Extinction Coefficient) 8 145.475 6.1 3.93
Vitros DT60/DT60 II/DTSC II 2 165.000 14.6 21.25 <= -60

0 50 100 150 200

Concentration

Issue No: 1 Issue Date: 30/10/2019 Page 6

A ABC
MONTHLY CLINICAL CHEMISTRY LABORATORY REF. NO. 87923/A CYCLE 16 SAMPLE 10 28/10/2019
Mean for Comparison

Bilirubin, Direct, mg/dl

I 1.045

I 1.679

I 1.016

I 0.962

I 1.001

I 0.999

I 1.568

I 1.003

I 1.841

I 1.047

I 1.034

I 1.623

I 0.969

I 0.465

I 1.533

I 0.968

I 1.721

I 1.143

I 0.967

I 1.669
>+3

N Mean CV% Um SDPA Exc.

+2

All Methods 4348 1.578 17.5 0.01 0.24 297

Diazo with Sulphanilic Acid 1670 1.619 16.1 0.01 0.24 165 +11

Standard Deviation
Thermo Konelab 20/30/60/Indiko 23 1.669 21.9 0.10 0.27a 2
0

-1
Your Result 1.200 SDI -1.74
RMSDI -1.98
-2

Mean for Comparison 1.669 TS 45

RMTS 47 <-3

N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10

%DEV -28.1 Sample Number

RM%DEV -31.3 TDPA = 24.8%

120

110

100

Acceptable limits derived from Biological Variation 44.5 % 90

Acceptable limits of performance for RIQAS 24.80 % 80

70

Target Score
TS & %DEV outside limits 60

50

40

30

20

10

N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10

Sample Number

600 >= 60

500 40
Number of Laboratories

20
400
% Deviation

0
300

-20
200

-40
100

<= -60

0 N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10
Sample Number
< 0.85 1.05 1.26 1.47 1.68 1.88 2.09 2.30 >
mg/dl
>= 60

Method N Mean CV% Um 40

Diazo with Sulphanilic Acid 1670 1.619 16.1 0.01

Dichlorophenyl Diazonium 1400 1.576 14.1 0.01 20

Diazo with Dichloroanaline 429 1.680 8.8 0.01

% Deviation

Diazo/ Sulphanilic Siemens Dimension 289 1.099 4.7 0.00

Oxidation to Biliverdin/Vanadate 197 1.868 8.2 0.01 0

Roche DPD JG standardised 104 1.807 3.3 0.01

Diazo/Sulphanilic Beckman DxC 71 1.021 7.1 0.01
Roche DPD Doumas standardised 71 1.662 10.4 0.03 -20

Other Dry Chemistry 16 2.051 22.2 0.14

Agappe - DIAZO 15 1.058 18.1 0.06
Roche (US calibrator only) 2 1.734 7.9 0.12 -40

<= -60

0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8 2.0

Concentration

Issue No: 1 Issue Date: 30/10/2019 Page 7

A ABC
MONTHLY CLINICAL CHEMISTRY LABORATORY REF. NO. 87923/A CYCLE 16 SAMPLE 10 28/10/2019
Mean for Comparison

Bilirubin, Total, mg/dl

I 1.571

I 4.937

I 1.513

I 1.582

I 1.418

I 1.405

I 5.448

I 1.484

I 5.897

I 1.464

I 1.477

I 4.929

I 1.429

I 0.979

I 4.971

I 1.548

I 5.480

I 1.696

I 1.547

I 5.035
>+3

N Mean CV% Um SDPA Exc.

+2

All Methods 4701 5.064 7.2 0.01 0.49 427

Diazo with Sulphanilic Acid 1923 5.117 7.3 0.01 0.50 194 +11

Standard Deviation
Thermo Konelab 20/30/60/Indiko 18 5.035 5.4 0.08 0.49 5
0

-1
Your Result 6.100 SDI 2.17
RMSDI -0.52
-2

Mean for Comparison 5.035 TS 38

RMTS 65 <-3

N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10

%DEV 21.1 Sample Number

RM%DEV -5.5 TDPA = 16%

120

110

100

Acceptable limits derived from Biological Variation 26.94 % 90

Acceptable limits of performance for RIQAS 16.00 % 80

70

Target Score
SDI in bottom 5% of peer group 60

TS & %DEV outside limits 50

40

30

20

10

N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10

Sample Number

700
>= 30

600
20
Number of Laboratories

500
10
% Deviation

400
0

300

-10

200

-20

100

<= -30

0 N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10
Sample Number
< 4.10 4.37 4.65 4.92 5.20 5.47 5.75 6.02 >
mg/dl
>= 30

Method N Mean CV% Um 20

Diazo with Sulphanilic Acid 1923 5.117 7.3 0.01

Dichlorophenyl Diazonium 936 4.864 6.4 0.01 10

DPD (Beckman AU) 510 5.173 3.1 0.01

% Deviation

Diazonium ion 450 4.846 5.8 0.02

Diazo with Dichloroaniline 422 5.281 6.9 0.02 0

Oxidation to Biliverdin/Vanadate 216 5.616 5.2 0.02

Ortho Vitros MicroSlide System Total Bil 156 4.786 4.4 0.02
Nitrobenzenediazonium Salt 21 5.036 5.3 0.07 -10

Other Dry Chemistry 18 4.610 4.2 0.06

Agappe - TAB 12 5.182 7.0 0.13
Agappe - DMSO 6 5.003 16.0 0.41 -20

Direct Spectrophotometry 4 5.002 4.2 0.13

Vitros DT60/DT60 II Total Bil 2 4.850 1.5 0.06
<= -30

0 1 2 3 4 5 6

Concentration

Issue No: 1 Issue Date: 30/10/2019 Page 8

A ABC
MONTHLY CLINICAL CHEMISTRY LABORATORY REF. NO. 87923/A CYCLE 16 SAMPLE 10 28/10/2019
Mean for Comparison

I 12.950

I 12.175

I 14.023

I 12.742

I 14.424

I 13.245

I 12.821
Calcium, mg/dl

I 8.803

I 8.666

I 8.690

I 8.933

I 8.638

I 8.510

I 8.900

I 8.633

I 8.583

I 6.162

I 8.725

I 8.833

I 8.699
>+3

N Mean CV% Um SDPA Exc.

+2

All Methods 3904 12.445 3.2 0.01 0.61 356

Arsenazo 1843 12.421 3.4 0.01 0.60 165 +11

Standard Deviation
Thermo Konelab 20/30/60/Indiko 27 12.821 3.5 0.11 0.62 2
0

-1
Your Result 14.000 SDI 1.89
RMSDI 0.32
-2

Mean for Comparison 12.821 TS 44

RMTS 83 <-3

N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10

%DEV 9.2 Sample Number

RM%DEV 1.6 TDPA = 8%

120

110

100

Acceptable limits derived from Biological Variation 2.55 % 90

Acceptable limits of performance for RIQAS 8.00 % 80

70

Target Score
TS & %DEV outside limits 60

50

40

30

20

10

N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10

Sample Number

600 >= 10

500
6
Number of Laboratories

4
400
2
% Deviation

0
300

-2

200 -4

-6

100
-8

<= -10

0 N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10
Sample Number
< 11.40 11.70 11.99 12.29 12.59 12.89 13.18 13.48 >
mg/dl
>= 10

Method N Mean CV% Um

6

Arsenazo 1843 12.421 3.4 0.01 4

Cresolphthalein complexone 1176 12.409 3.3 0.01
NM-BAPTA 542 12.555 2.0 0.01 2
% Deviation

Ortho Vitros MicroSlide Systems 171 12.570 2.2 0.03

Ion selective electrode 95 12.259 3.3 0.05 0

Methylthymol blue 15 12.395 3.9 0.16

Other Dry Chemistry 15 13.219 6.0 0.25 -2

Phosphonazo 14 12.176 3.7 0.15

-4
Agappe - ARSENAZO 12 12.304 3.1 0.14
Atomic absorption 3 11.853 9.3 0.80 -6
Agappe - OCPC 3 12.140 6.8 0.59
Vitros DT60/DT60 II/DTSC II 2 12.250 2.9 0.31 -8

<= -10

0 2 4 6 8 10 12 14 16

Concentration

Issue No: 1 Issue Date: 30/10/2019 Page 9

A ABC
MONTHLY CLINICAL CHEMISTRY LABORATORY REF. NO. 87923/A CYCLE 16 SAMPLE 10 28/10/2019
Mean for Comparison

I 112.371

I 102.025

I 114.640

I 104.713

I 118.143

I 101.867

I 104.560

I 120.283

I 102.817

I 119.763

I 105.500

I 121.800

I 105.867

I 104.183

I 119.867
I 97.400

I 99.875

I 99.200

I 98.050

I 86.375
Chloride, mmol/l
>+3

N Mean CV% Um SDPA Exc.

+2

All Methods 3154 118.609 2.4 0.06 3.32 285

ISE, direct 794 118.745 3.1 0.17 3.32 70 +11

Standard Deviation
Other ISE Instruments 6 119.867 2.2 1.36 3.62a 0
0

-1
Your Result 120.000 SDI 0.04
RMSDI -0.50
-2

Mean for Comparison 119.867 TS 120

RMTS 58 <-3

N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10

%DEV 0.1 Sample Number

RM%DEV -2.1 TDPA = 4.6%

120

110

100

Acceptable limits derived from Biological Variation 1.5 % 90

Acceptable limits of performance for RIQAS 4.60 % 80

70

Target Score
60

50

40

30

20

10

N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10

Sample Number
450

400 >= 10

8
350
6
Number of Laboratories

300
4

250 2
% Deviation

0
200

-2

150
-4

100 -6

-8
50

<= -10

0 N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10
Sample Number
< 111.11 113.25 115.39 117.53 119.67 121.82 123.96 126.10 >
mmol/l
>= 10

Method N Mean CV% Um

6

ISE, indirect 2108 118.569 2.0 0.06 4

ISE, direct 794 118.745 3.1 0.17
Colorimetric 134 114.570 4.8 0.59 2
% Deviation

Ortho Vitros MicroSlide Systems 115 120.948 1.7 0.24

Other Dry Chemistry 14 120.641 2.3 0.94 0

Optical Fluorescence 12 131.542 2.0 0.93

Agappe - THIOCYANATE 6 105.583 1.2 0.67 -2

-4

-6

-8

<= -10

40 60 80 100 120 140 160

Concentration

Issue No: 1 Issue Date: 30/10/2019 Page 10

A ABC
MONTHLY CLINICAL CHEMISTRY LABORATORY REF. NO. 87923/A CYCLE 16 SAMPLE 10 28/10/2019
Mean for Comparison

I 152.087

I 293.618

I 154.992

I 155.942

I 146.558

I 158.443

I 266.257

I 155.282

I 308.246

I 144.319

I 146.303

I 274.410

I 153.632

I 254.275

I 146.732

I 282.372

I 152.528

I 151.211

I 269.125
I 99.598
Cholesterol, mg/dl
>+3

N Mean CV% Um SDPA Exc.

+2

All Methods 5138 269.327 4.3 0.20 15.39 410

Cholesterol Oxidase - Abell Kendall 4250 270.222 4.3 0.22 15.44 338 +11

Standard Deviation
Thermo Konelab 20/30/60/Indiko 38 269.125 4.4 2.42 15.38 4
0

-1
Your Result 282.000 SDI 0.84
RMSDI -0.28
-2

Mean for Comparison 269.125 TS 79

RMTS 98 <-3

N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10

%DEV 4.8 Sample Number

RM%DEV -1.4 TDPA = 9.4%

120

110

100

Acceptable limits derived from Biological Variation 9.01 % 90

Acceptable limits of performance for RIQAS 9.40 % 80

70

Target Score
60

50

40

30

20

10

N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10

Sample Number
900

800 >= 15

700
10
Number of Laboratories

600

500
% Deviation

0
400

300 -5

200
-10

100

<= -15

0 N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10
Sample Number
< 238.96 247.64 256.31 264.98 273.66 282.33 291.01 299.68 >
mg/dl
>= 15

Method N Mean CV% Um 10

Cholesterol Oxidase - Abell Kendall 4250 270.222 4.3 0.22

Cholesterol Oxidase - IDMS 400 270.143 4.1 0.70 5

Siemens Dimension 206 259.118 2.4 0.55

% Deviation

Ortho Vitros MicroSlide Systems 168 258.698 2.8 0.70

Cholesterol Dehydrogenase 43 270.123 3.5 1.80 0

Agappe - CHOD-PAP 32 273.267 4.6 2.77

Other Dry Chemistry 24 259.645 5.6 3.73
Dimension - non Siemens reagents 2 255.923 1.1 2.59 -5

Vitros DT60/DT60 II/DTSC II 2 254.346 1.9 4.18

-10

<= -15

40 90 140 190 240 290 340

Concentration

Issue No: 1 Issue Date: 30/10/2019 Page 11

A ABC
MONTHLY CLINICAL CHEMISTRY LABORATORY REF. NO. 87923/A CYCLE 16 SAMPLE 10 28/10/2019
Mean for Comparison

M 194.144

M 492.403

M 189.153

M 207.503

M 195.749

M 199.551

M 503.688

M 198.474

M 514.140

M 201.995

M 200.708

M 489.689

M 195.868

M 454.043

M 188.563

M 497.027

M 181.868

M 203.436

M 484.921
M 87.253
CK, Total, U/l @ 37°C
>+3

N Mean CV% Um SDPA Exc.

+2

All Methods 2760 475.098 6.0 0.68 34.95 278

CK-NAC serum start (DGKC) 83 484.921 6.8 4.50 35.67 12 +11

Standard Deviation
Thermo Konelab 20/30/60/Indiko 3 384.200 59.4 164.60 167.01a 0
0

-1
Your Result 121.000 SDI -10.20
RMSDI -8.85
-2

Mean for Comparison 484.921 TS 10

RMTS 19 <-3

N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10

%DEV -75.0 Sample Number

RM%DEV -63.9 TDPA = 12.1%

120

110

100

Acceptable limits derived from Biological Variation 30.3 % 90

Acceptable limits of performance for RIQAS 12.10 % 80

70

Target Score
SDI in bottom 5% of peer group 60

TS & %DEV outside limits 50

40

30

20

10

N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10

Sample Number

400

>= 100

350
80

300 60
Number of Laboratories

40
250
20
% Deviation

200
0

-20
150

-40

100
-60

50 -80

<= -100

0 N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10
Sample Number
< 400.55 421.85 443.15 464.44 485.74 507.04 528.34 549.63 >
U/l
>= 100

80

Method N Mean CV% Um

60

CK-NAC (IFCC) 1838 473.846 5.6 0.77 40

Abbott CK-NAC (IFCC) 227 485.483 3.2 1.31
Beckman CK-NAC (IFCC) 166 497.488 4.1 1.97 20
% Deviation

CK-NAC substrate start (DGKC) 133 471.118 5.6 2.86

Ortho Vitros MicroSlide Systems 124 406.661 8.7 3.99 0

Creatine phosphate substrate start 98 464.739 4.8 2.84

CK-NAC serum start (DGKC) 83 484.921 6.8 4.50 -20

Monothioglycerol 50 494.589 4.6 4.03

-40
Agappe - IFCC/KINETIC 13 477.491 5.6 9.34
Other Dry Chemistry 12 544.712 13.2 25.90 -60
Beckman CK-NAC (Extinction Coeff) 8 492.214 1.9 4.15
Dithioerythritol (DTE), IFCC correlated 6 457.983 2.1 4.93 -80

<= -100

40 140 240 340 440 540

Concentration

Issue No: 1 Issue Date: 30/10/2019 Page 12

A ABC
MONTHLY CLINICAL CHEMISTRY LABORATORY REF. NO. 87923/A CYCLE 16 SAMPLE 10 28/10/2019
Mean for Comparison

Creatinine, mg/dl

I 1.411

I 4.043

I 1.347

I 1.538

I 1.402

I 1.424

I 4.206

I 1.495

I 6.180

I 1.433

I 1.611

I 3.880

I 1.491

I 0.944

I 6.626

I 1.588

I 3.902

I 1.473

I 1.481

I 4.051
>+3

N Mean CV% Um SDPA Exc.

+2

All Methods 5507 4.209 7.0 0.00 0.32 434

Alkaline picrate no deproteinisation 1846 4.158 8.2 0.01 0.31 137 +11

Standard Deviation
Thermo Konelab 20/30/60/Indiko 13 4.051 10.4 0.15 0.34a 0
0

-1
Your Result 4.700 SDI 1.92
RMSDI 0.04
-2

Mean for Comparison 4.051 TS 39

RMTS 77 <-3

N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10

%DEV 16.0 Sample Number

RM%DEV 0.4 TDPA = 12.4%

120

110

100

Acceptable limits derived from Biological Variation 8.87 % 90

Acceptable limits of performance for RIQAS 12.40 % 80

70

Target Score
TS & %DEV outside limits 60

50

40

30

20

10

N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10

Sample Number

800

>= 15

700

10
600
Number of Laboratories

500 5
% Deviation

400
0

300
-5

200

-10

100

<= -15

0 N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10
Sample Number
< 3.43 3.65 3.87 4.09 4.31 4.54 4.76 4.98 >
mg/dl
>= 15

Method N Mean CV% Um 10

Alkaline picrate no deproteinisation 1846 4.158 8.2 0.01

Jaffe rate blanked 1252 4.073 6.5 0.01 5

Jaffe rate blanked comp. (-26umol/l) 517 4.331 4.4 0.01

% Deviation

Jaffe rate comp. (-18umol/l) 459 4.211 4.2 0.01

Roche Creatinine Plus 247 4.431 3.2 0.01 0

Enzymatic UV method (340nm) 222 4.363 5.2 0.02

Creatinine PAP method 204 4.310 5.3 0.02
IDMS traceable 167 4.290 5.4 0.02 -5

Vitros, IDMS traceable 149 4.541 3.1 0.01

Other enzymatic methods 126 4.453 3.7 0.02
Alkaline picrate with deproteinisation 105 4.057 7.8 0.04 -10

Jaffe rate blanked comp. (-33umol/l) 88 3.917 7.4 0.04

Other Dry Chemistry 35 4.339 7.7 0.07
Agappe - JAFFE'S KINETIC 23 3.712 8.5 0.08 <= -15

Vitros DT60/DT60 II/DTSC II 13 4.547 5.2 0.08 0 1 2 3 4 5 6 7

Agappe - ENZYMATIC 12 3.950 15.3 0.22
Concentration

Issue No: 1 Issue Date: 30/10/2019 Page 13

A ABC
MONTHLY CLINICAL CHEMISTRY LABORATORY REF. NO. 87923/A CYCLE 16 SAMPLE 10 28/10/2019
Mean for Comparison

I 109.993

I 277.530

I 112.207

I 110.153

I 113.924

I 116.047

I 278.697

I 110.638

I 356.501

I 112.482

I 108.944

I 282.806

I 112.256

I 345.584

I 110.182

I 280.415

I 113.898

I 109.794

I 281.941
I 39.448
Glucose, mg/dl
>+3

N Mean CV% Um SDPA Exc.

+2

All Methods 5527 278.970 3.9 0.18 14.42 474

Glucose oxidase 2379 277.370 5.3 0.38 14.33 225 +11

Standard Deviation
Thermo Konelab 20/30/60/Indiko 41 281.941 4.1 2.24 14.57 5
0

-1
Your Result 312.000 SDI 2.06
RMSDI 0.17
-2

Mean for Comparison 281.941 TS 40

RMTS 62 <-3

N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10

%DEV 10.7 Sample Number

RM%DEV 1.0 TDPA = 8.5%

120

110

100

Acceptable limits derived from Biological Variation 6.96 % 90

Acceptable limits of performance for RIQAS 8.50 % 80

70

Target Score
SDI in bottom 5% of peer group 60

TS & %DEV outside limits 50

40

30

20

10

N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10

Sample Number
1000

>= 20

800
15
Number of Laboratories

10

600
5
% Deviation

400
-5

-10

200
-15

<= -20

0 N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10
Sample Number
< 250.68 258.76 266.84 274.92 283.01 291.09 299.17 307.25 >
mg/dl
>= 20

15
Method N Mean CV% Um
10
Hexokinase 2772 280.588 2.5 0.16
Glucose oxidase 2379 277.370 5.3 0.38
5
Ortho Vitros MicroSlide Systems 173 263.856 2.1 0.54
% Deviation

Glucose dehydrogenase 66 279.128 4.1 1.77

Agappe - GOD-PAP 35 282.872 5.1 3.05 0

Oxygen electrode 29 276.002 2.2 1.39

Other Dry Chemistry 22 272.429 2.7 1.97 -5
GOD/02-Beckman method 21 275.503 1.8 1.35
Vitros, DT60/DT60 II 2 270.286 4.3 10.36
-10

-15

<= -20

10 60 110 160 210 260 310 360

Concentration

Issue No: 1 Issue Date: 30/10/2019 Page 14

A ABC
MONTHLY CLINICAL CHEMISTRY LABORATORY REF. NO. 87923/A CYCLE 16 SAMPLE 10 28/10/2019
Mean for Comparison

I 130.403

I 104.826

I 106.681

I 115.627

I 123.212

I 123.986

I 111.766
I 47.981

I 48.188

I 50.405

I 42.782

I 54.673

I 46.761

I 43.995

I 52.696

I 47.702

I 79.486

I 50.930

I 47.637

I 58.840
HDL-Cholesterol, mg/dl
>+3

N Mean CV% Um SDPA Exc.

+2

All Methods 4060 103.729 16.8 0.34 12.55 217

Direct HDL, PEGME 421 97.547 18.6 1.11 11.80 22 +11

Standard Deviation
Thermo Konelab 20/30/60/Indiko 15 111.766 11.3 4.07 14.12a 0
0

-1
Your Result 132.000 SDI 1.43
RMSDI 0.76
-2

Mean for Comparison 111.766 TS 54

RMTS 66 <-3

N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10

%DEV 18.1 Sample Number

RM%DEV 9.4 TDPA = 19.9%

120

110

100

Acceptable limits derived from Biological Variation 11.63 % 90

Acceptable limits of performance for RIQAS 19.90 % 80

70

Target Score
60

50

40

30

20

10

N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10

Sample Number

600
>= 30

500
20
Number of Laboratories

400
10
% Deviation

300 0

-10
200

-20
100

<= -30

0 N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10
Sample Number
< 57.99 71.06 84.12 97.19 110.26 123.32 136.39 149.46 >
mg/dl
>= 30

Method N Mean CV% Um 20

Direct HDL, Roche 4th gen. 959 125.996 4.8 0.25

Direct HDL, Immunoseparation 846 99.253 11.2 0.48 10

Direct HDL, Clearance method 783 91.968 14.4 0.59

% Deviation

HDL Ultra/Accel Selective Detergent 393 96.628 6.1 0.37

Direct HDL, PEGME 421 97.547 18.6 1.11 0

Direct HDL, PPD 290 100.851 11.6 0.85

Vitros dHDL, PTA/MgCl2 direct precip. 130 84.580 7.4 0.68
Other Dry Chemistry 39 99.436 13.8 2.74 -10

Agappe - SELECTIVE INHIBITION 29 116.090 14.4 3.87

Vitros, Magnetic HDL 20 89.347 9.0 2.23
Vitros 5.1 FS Microtip assay 15 85.320 6.6 1.82 -20

<= -30

20 40 60 80 100 120 140

Concentration

Issue No: 1 Issue Date: 30/10/2019 Page 15

A ABC
MONTHLY CLINICAL CHEMISTRY LABORATORY REF. NO. 87923/A CYCLE 16 SAMPLE 10 28/10/2019
Mean for Comparison

A 260.018

A 104.988

A 235.347

A 116.256

A 120.700

A 229.772
A 19.027

A 41.148

A 19.004

A 19.513

A 18.603

A 18.147

A 36.441

A 19.653

A 76.344

A 18.584

A 18.551

A 39.027

A 19.750

A 93.504
Iron, ug/dl
>+3

N Mean CV% Um SDPA Exc.

+2

All Methods 2472 229.772 3.9 0.23 13.55 221

Agappe - CHROMAZUROL 2 205.760 4.6 8.45 14.79a 1 +11

Standard Deviation
Agappe Mispa Nano 0
0

-1
Your Result 328.000 SDI 7.25
RMSDI Too Few
-2

Mean for Comparison 229.772 TS 10

RMTS Too Few <-3

N N N N N N N N N N N 2 3 4 5 6 7 N N 10

%DEV 42.8 Sample Number

RM%DEV Too Few TDPA = 9.7%

120

110

100

Acceptable limits derived from Biological Variation 30.7 % 90

Acceptable limits of performance for RIQAS 9.70 % 80

70

Target Score
SDI in bottom 5% of peer group 60

TS & %DEV outside limits 50

40

30

20

10

N N N N N N N N N N N 2 3 4 5 6 7 N N 10

Sample Number

400
>= 30

350

20

300
Number of Laboratories

10
250
% Deviation

200 0

150
-10

100
-20

50

<= -30

0 N N N N N N N N N N N 2 3 4 5 6 7 N N 10
Sample Number
< 206.27 212.99 219.70 226.41 233.12 239.84 246.55 253.26 >
ug/dl
>= 30

Method N Mean CV% Um 20

Colorimetric without ppt. 1999 230.285 3.9 0.25

Colorimetric with ppt. 309 228.468 3.6 0.58 10

Ortho Vitros MicroSlide Systems 111 224.072 4.3 1.15

% Deviation

Other method with blank 32 229.146 3.1 1.58

Other method without blank 12 231.924 4.3 3.63 0

Other Dry Chemistry 6 233.059 3.2 3.81

Agappe - CHROMAZUROL 2 205.760 4.6 8.45
-10

-20

<= -30

0 50 100 150 200 250

Concentration

Issue No: 1 Issue Date: 30/10/2019 Page 16

A ABC
MONTHLY CLINICAL CHEMISTRY LABORATORY REF. NO. 87923/A CYCLE 16 SAMPLE 10 28/10/2019
Mean for Comparison

M 2.430

M 3.077

M 2.118

M 2.123

M 2.214

M 2.145

M 3.318

M 2.216

M 3.320

M 2.056

M 2.076

M 3.306

M 2.165

M 1.397

M 2.713

M 2.010

M 3.213

M 2.193

M 2.175

M 3.386
Magnesium, mg/dl
>+3

N Mean CV% Um SDPA Exc.

+2

All Methods 2381 4.053 3.8 0.00 0.28 267

Agappe - XYLIDYL BLUE 12 3.386 24.2 0.30 0.38a 0 +11

Standard Deviation
Agappe Mispa Nano 3 3.433 36.4 0.90 0.93a 0
0

-1
Your Result 2.000 SDI -3.69
RMSDI Too Few
-2

Mean for Comparison 3.386 TS 10

RMTS Too Few <-3

N N N N N N N N N N N N N 4 5 6 7 N N 10

%DEV -40.9 Sample Number

RM%DEV Too Few TDPA = 11.2%

120

110

100

Acceptable limits derived from Biological Variation 4.8 % 90

Acceptable limits of performance for RIQAS 11.20 % 80

70

Target Score
SDI in bottom 5% of peer group 60

TS & %DEV outside limits 50

40

30

20

10

N N N N N N N N N N N N N 4 5 6 7 N N 10

Sample Number

400

>= 60
350

40
300
Number of Laboratories

250 20
% Deviation

200
0

150
-20

100

-40

50

<= -60

0 N N N N N N N N N N N N N 4 5 6 7 N N 10
Sample Number
< 3.64 3.76 3.87 3.99 4.11 4.22 4.34 4.46 >
mg/dl
>= 60

Method N Mean CV% Um 40

Xylidyl Blue 1138 4.047 4.5 0.01

Chlorphosphonazo III 372 4.061 2.3 0.01 20

Methylthymol blue 246 4.026 3.6 0.01

% Deviation

Enzymatic 228 4.036 2.6 0.01

Calmagite 132 3.911 5.7 0.02 0

Ortho Vitros MicroSlide Systems 140 4.196 3.5 0.02

Arsenazo 85 4.022 3.4 0.02
Atomic absorption 21 4.076 3.2 0.04 -20

Other Dry Chemistry 19 4.279 8.8 0.11

Agappe - XYLIDYL BLUE 12 3.386 24.2 0.30
Other magnesium dyes 4 3.927 4.4 0.11 -40

<= -60

0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0

Concentration

Issue No: 1 Issue Date: 30/10/2019 Page 17

A ABC
MONTHLY CLINICAL CHEMISTRY LABORATORY REF. NO. 87923/A CYCLE 16 SAMPLE 10 28/10/2019
Mean for Comparison

Phosphate, Inorganic, mg/dl

I 4.313

I 6.647

I 4.554

I 4.702

I 4.503

I 5.038

I 5.964

I 4.721

I 7.914

I 4.951

I 4.510

I 6.305

I 4.581

I 2.370

I 6.265

I 4.250

I 6.519

I 4.651

I 4.478

I 5.776
>+3

N Mean CV% Um SDPA Exc.

+2

All Methods 2680 6.771 3.3 0.01 0.35 270

Phosphomolybdate UV 2269 6.766 3.3 0.01 0.35 228 +11

Standard Deviation
Erba-Chem EC-5/EC-7 11 5.776 16.9 0.37 0.48a 0
0

-1
Your Result 6.500 SDI 1.52
RMSDI -0.27
-2

Mean for Comparison 5.776 TS 34

RMTS 45 <-3

N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10

%DEV 12.5 Sample Number

RM%DEV -2.7 TDPA = 8.6%

120

110

100

Acceptable limits derived from Biological Variation 10.11 % 90

Acceptable limits of performance for RIQAS 8.60 % 80

70

Target Score
TS & %DEV outside limits 60

50

40

30

20

10

N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10

Sample Number

450

>= 30
400

350 20
Number of Laboratories

300
10

250
% Deviation

0
200

150 -10

100
-20

50

<= -30

0 N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10
Sample Number
< 6.18 6.35 6.51 6.68 6.85 7.02 7.19 7.35 >
mg/dl
>= 30

Method N Mean CV% Um 20

Phosphomolybdate UV 2269 6.766 3.3 0.01

Phosphomolybdate enzymatic 206 6.766 3.2 0.02 10

Ortho Vitros MicroSlide Systems 141 6.840 3.2 0.02

% Deviation

Beckman PHOSm kit (365nm) 25 6.785 3.5 0.06

Agappe - PHOSPOHMOLYBDATE 12 6.775 2.2 0.05 0

Other Dry Chemistry 10 7.427 2.9 0.09

Other methods, no protein ppt 10 6.881 4.2 0.12
Vitros, DT60/DT60 II/DTSC II 4 6.853 3.4 0.14 -10

-20

<= -30

0 1 2 3 4 5 6 7 8 9

Concentration

Issue No: 1 Issue Date: 30/10/2019 Page 18

A ABC
MONTHLY CLINICAL CHEMISTRY LABORATORY REF. NO. 87923/A CYCLE 16 SAMPLE 10 28/10/2019
Mean for Comparison

Potassium, mmol/l

I 3.653

I 5.871

I 3.804

I 3.829

I 3.916

I 3.960

I 5.941

I 3.964

I 6.598

I 3.990

I 3.940

I 5.870

I 3.915

I 2.109

I 5.824

I 3.823

I 5.994

I 3.843

I 3.964

I 5.926
>+3

N Mean CV% Um SDPA Exc.

+2

All Methods 3548 6.226 2.5 0.00 0.20 268

ISE method - direct 1078 6.173 3.3 0.01 0.20 96 +11

Standard Deviation
Other ISE Instruments 8 5.926 7.1 0.18 0.27a 0
0

-1
Your Result 5.300 SDI -2.36
RMSDI -0.76
-2

Mean for Comparison 5.926 TS 20

RMTS 63 <-3

N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10

%DEV -10.6 Sample Number

RM%DEV -3.1 TDPA = 5.3%

120

110

100

Acceptable limits derived from Biological Variation 5.61 % 90

Acceptable limits of performance for RIQAS 5.30 % 80

70

Target Score
SDI in bottom 5% of peer group 60

TS & %DEV outside limits 50

40

30

20

10

N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10

Sample Number
700

>= 8
600

500
Number of Laboratories

400 2
% Deviation

0
300

-2

200
-4

100 -6

<= -8

0 N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10
Sample Number
< 5.81 5.93 6.05 6.16 6.28 6.40 6.51 6.63 >
mmol/l
>= 8

6
Method N Mean CV% Um
4
ISE method - indirect 2190 6.250 1.8 0.00
ISE method - direct 1078 6.173 3.3 0.01
2
Ortho Vitros MicroSlide Systems 139 6.226 1.8 0.01
% Deviation

Colorimetric 57 5.540 8.5 0.08

Flame photometry 21 6.093 4.0 0.07 0

Other Dry Chemistry 17 6.303 3.0 0.06

Optical Fluorescence 12 6.571 2.5 0.06 -2
Enzymatic 9 6.099 7.0 0.18
Turbidimetric 7 6.071 6.2 0.18
-4
Vitros, DT60/DT60 II/DTE II 4 6.300 2.9 0.11
Chromolyte 2 6.260 0.0 0.00
-6

<= -8

0 1 2 3 4 5 6 7

Concentration

Issue No: 1 Issue Date: 30/10/2019 Page 19

A ABC
MONTHLY CLINICAL CHEMISTRY LABORATORY REF. NO. 87923/A CYCLE 16 SAMPLE 10 28/10/2019
Mean for Comparison

Protein, Total, g/dl

I 5.956

I 4.740

I 5.954

I 5.858

I 5.876

I 5.802

I 4.611

I 5.902

I 8.085

I 5.782

I 5.886

I 4.583

I 5.891

I 3.824

I 7.704

I 5.797

I 4.664

I 5.961

I 5.781

I 4.903
>+3

N Mean CV% Um SDPA Exc.

+2

All Methods 4423 4.873 4.1 0.00 0.25 403

Biuret reaction, end point 4055 4.866 4.2 0.00 0.25 350 +11

Standard Deviation
Thermo Konelab 20/30/60/Indiko 36 4.903 4.1 0.04 0.26 5
0

-1
Your Result 4.900 SDI -0.01
RMSDI 0.51
-2

Mean for Comparison 4.903 TS 120

RMTS 90 <-3

N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10

%DEV -0.1 Sample Number

RM%DEV 2.5 TDPA = 8.6%

120

110

100

Acceptable limits derived from Biological Variation 3.63 % 90

Acceptable limits of performance for RIQAS 8.60 % 80

70

Target Score
60

50

40

30

20

10

N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10

Sample Number
800

>= 15
700

10
600
Number of Laboratories

500 5
% Deviation

400
0

300
-5

200

-10

100

<= -15

0 N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10
Sample Number
< 4.34 4.49 4.64 4.79 4.94 5.09 5.24 5.39 >
g/dl
>= 15

Method N Mean CV% Um 10

Biuret reaction, end point 4055 4.866 4.2 0.00

Ortho Vitros MicroSlide Systems 163 4.981 3.1 0.01 5

Biuret reaction, kinetic 131 4.833 3.7 0.02

% Deviation

Biuret reaction, CX4/5/7 39 4.824 3.3 0.03

Agappe - BIURET 26 4.946 2.7 0.03 0

Other Dry Chemistry 13 5.223 3.8 0.07

Vitros, DT60/DT60 II 2 4.800 0.0 0.00
-5

-10

<= -15

0 1 2 3 4 5 6 7 8 9

Concentration

Issue No: 1 Issue Date: 30/10/2019 Page 20

A ABC
MONTHLY CLINICAL CHEMISTRY LABORATORY REF. NO. 87923/A CYCLE 16 SAMPLE 10 28/10/2019
Mean for Comparison

I 142.600

I 158.167

I 141.371

I 140.311

I 145.200

I 141.120

I 158.225

I 145.267

I 162.900

I 141.600

I 139.686

I 157.400

I 137.586

I 111.665

I 154.709

I 137.875

I 155.416

I 141.957

I 142.550

I 157.188
Sodium, mmol/l
>+3

N Mean CV% Um SDPA Exc.

+2

All Methods 3471 159.231 1.8 0.06 3.39 318

ISE method - direct 1068 158.156 2.0 0.12 3.37 103 +11

Standard Deviation
Other ISE Instruments 8 157.188 1.7 1.19 3.55a 0
0

-1
Your Result 156.300 SDI -0.25
RMSDI 0.07
-2

Mean for Comparison 157.188 TS 120

RMTS 92 <-3

N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10

%DEV -0.6 Sample Number

RM%DEV 0.2 TDPA = 3.5%

120

110

100

Acceptable limits derived from Biological Variation 0.73 % 90

Acceptable limits of performance for RIQAS 3.50 % 80

70

Target Score
60

50

40

30

20

10

N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10

Sample Number

500

>= 5

400
3
Number of Laboratories

300
1
% Deviation

200 -1

-3
100

<= -5

0 N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10
Sample Number
< 151.85 153.96 156.06 158.17 160.28 162.39 164.50 166.60 >
mmol/l
>= 5

Method N Mean CV% Um

3

ISE method - indirect 2181 159.819 1.5 0.06

ISE method - direct 1068 158.156 2.0 0.12
Ortho Vitros MicroSlide Systems 142 155.897 1.5 0.24 1
% Deviation

Colorimetric 45 149.496 3.6 1.01

Flame photometry 20 159.197 1.9 0.85
Other Dry Chemistry 14 158.257 2.0 1.04
Optical Fluorescence 13 159.954 1.3 0.74 -1

Enzymatic 5 156.120 6.4 5.57

Vitros, DT60/DT60 II/DTE II 3 159.000 2.9 3.31
Chromolyte 2 159.500 0.0 0.00 -3

<= -5

50 70 90 110 130 150 170 190 210

Concentration

Issue No: 1 Issue Date: 30/10/2019 Page 21

A ABC
MONTHLY CLINICAL CHEMISTRY LABORATORY REF. NO. 87923/A CYCLE 16 SAMPLE 10 28/10/2019
Mean for Comparison

M 256.540

M 247.586

M 104.402

M 414.601

M 244.949

M 105.256

M 368.744

M 267.764

M 102.312

M 247.165
M 96.659

M 96.463

M 97.108

M 95.165

M 98.468

M 94.812

M 97.780

M 25.317

M 98.302

M 93.624
Trig Total, mg/dl
>+3

N Mean CV% Um SDPA Exc.

+2

All Methods 4870 247.169 4.7 0.20 18.93 524

Lipase/GK UV. no correction 418 247.165 3.8 0.57 18.93 45 +11

Standard Deviation
Thermo Konelab 20/30/60/Indiko 4 249.022 5.2 8.05 20.70a 0
0

-1
Your Result 253.000 SDI 0.31
RMSDI 0.92
-2

Mean for Comparison 247.165 TS 120

RMTS 94 <-3

N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10

%DEV 2.4 Sample Number

RM%DEV 7.4 TDPA = 12.6%

120

110

100

Acceptable limits derived from Biological Variation 25.99 % 90

Acceptable limits of performance for RIQAS 12.60 % 80

70

Target Score
60

50

40

30

20

10

N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10

Sample Number
900

800 >= 40

30
700
Number of Laboratories

20
600

10
500
% Deviation

0
400

-10
300

-20
200

-30
100

<= -40

0 N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10
Sample Number
< 216.97 225.59 234.22 242.85 251.48 260.11 268.73 277.36 >
mg/dl
>= 40

30
Method N Mean CV% Um
20
Lipase/GPO-PAP no correction 3685 246.525 4.2 0.21
Lipase/GK UV. no correction 418 247.165 3.8 0.57
10
Lipase/GPO-PAP, 0.11mmol/l correction 252 246.207 5.1 0.99
% Deviation

Lipase/Glycerol Dehydrogenase 208 249.384 4.4 0.95

Ortho Vitros MicroSlide Systems 168 276.502 3.6 0.96 0

Lipase/GK UV., 0.11 mmol/l correction 52 242.826 3.9 1.64

Agappe - GPO - TOPS 30 239.705 4.7 2.55 -10
Other Dry Chemistry 25 294.567 15.1 11.10
Siemens Dimension 8 246.170 1.2 1.32
-20
Vitros DT60/DT60 II/DTSC II 3 291.829 10.4 21.88

-30

<= -40

10 60 110 160 210 260 310 360 410

Concentration

Issue No: 1 Issue Date: 30/10/2019 Page 22

A ABC
MONTHLY CLINICAL CHEMISTRY LABORATORY REF. NO. 87923/A CYCLE 16 SAMPLE 10 28/10/2019
Mean for Comparison

I 117.469

I 113.280

I 141.938

I 112.907

I 147.072

I 117.437

I 122.745
I 42.642

I 43.045

I 42.260

I 45.633

I 46.104

I 45.373

I 46.581

I 43.685

I 46.884

I 14.021

I 42.631

I 43.547

I 44.586
Urea, mg/dl
>+3

N Mean CV% Um SDPA Exc.

+2

All Methods 5394 125.945 5.5 0.12 9.34 440

Urease, kinetic 4678 126.487 5.3 0.12 9.38 374 +11

Standard Deviation
Thermo Konelab 20/30/60/Indiko 28 122.745 4.9 1.41 9.10 5
0

-1
Your Result 128.000 SDI 0.58
RMSDI 0.34
-2

Mean for Comparison 122.745 TS 95

RMTS 69 <-3

N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10

%DEV 4.3 Sample Number

RM%DEV 2.6 TDPA = 12.2%

120

110

100

Acceptable limits derived from Biological Variation 15.55 % 90

Acceptable limits of performance for RIQAS 12.20 % 80

70

Target Score
60

50

40

30

20

10

N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10

Sample Number
900

>= 20
800

15
700
Number of Laboratories

10
600

5
500
% Deviation

0
400

-5
300

-10
200

-15
100

<= -20

0 N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10
Sample Number
< 107.67 112.89 118.11 123.33 128.55 133.77 138.99 144.21 >
mg/dl
>= 20

15
Method N Mean CV% Um
10
Urease, kinetic 4678 126.487 5.3 0.12
Urease, end point 322 125.110 6.0 0.52
5
Ortho Vitros MicroSlide Systems 170 118.182 2.7 0.30
% Deviation

Urease, hypochlorite 119 118.208 7.6 1.03

Beckman - Conductivity 32 126.862 3.6 1.01 0

Agappe - UREASE GLDH 26 120.938 7.2 2.12

Other Dry Chemistry 18 130.928 4.1 1.59 -5
Agappe - BERTHELOT 3 114.229 5.5 4.57
Diacetyl monoxime 4 125.379 4.3 3.41
-10
O-Phthalaldehyde 4 127.275 6.6 5.28
Vitros DT60/DT60 II 2 116.843 5.9 6.05
-15

<= -20

0 20 40 60 80 100 120 140

Concentration

Issue No: 1 Issue Date: 30/10/2019 Page 23

A ABC
MONTHLY CLINICAL CHEMISTRY LABORATORY REF. NO. 87923/A CYCLE 16 SAMPLE 10 28/10/2019
Mean for Comparison

Uric Acid (Urate), mg/dl

I 6.051

I 9.456

I 5.815

I 6.015

I 6.254

I 6.056

I 9.026

I 5.922

I 9.875

I 6.210

I 5.804

I 9.884

I 6.050

I 3.123

I 9.595

I 5.782

I 8.943

I 6.312

I 5.821

I 9.258
>+3

N Mean CV% Um SDPA Exc.

+2

All Methods 4974 9.339 4.6 0.01 0.60 488

Uricase perox. no ascorb. ox. 2170 9.299 4.9 0.01 0.60 224 +11

Standard Deviation
Thermo Konelab 20/30/60/Indiko 16 9.258 4.6 0.13 0.60 3
0

-1
Your Result 9.200 SDI -0.10
RMSDI -0.00
-2

Mean for Comparison 9.258 TS 120

RMTS 80 <-3

N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10

%DEV -0.6 Sample Number

RM%DEV 0.0 TDPA = 10.6%

120

110

100

Acceptable limits derived from Biological Variation 11.97 % 90

Acceptable limits of performance for RIQAS 10.60 % 80

70

Target Score
60

50

40

30

20

10

N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10

Sample Number
800

700 >= 15

600 10
Number of Laboratories

500
5
% Deviation

400
0

300
-5

200

-10

100

<= -15

0 N 4 N 6 7 N N N 11 N 1 2 3 4 5 6 7 N N 10
Sample Number
< 8.21 8.53 8.85 9.17 9.49 9.82 10.14 10.46 >
mg/dl
>= 15

Method N Mean CV% Um 10

Uricase perox. no ascorb. ox. 2170 9.299 4.9 0.01

Uricase Perox. with ascorb. ox 1448 9.461 4.2 0.01 5

Uricase Perox. with ascorb. ox @ 546nm 843 9.307 4.1 0.02

% Deviation

Ortho Vitros MicroSlide Systems 170 8.906 2.9 0.02

Uricase @ 293 nm 149 9.429 2.0 0.02 0

Uricase, catalase 340nm. 115 9.379 2.4 0.03

Other Dry Chemistry 19 10.259 3.4 0.10
Agappe - URICASE - TOPS 18 9.065 9.2 0.24 -5

Reduction methods 15 9.591 7.1 0.22

Agappe - URICASE - PAP 9 9.312 11.4 0.44
Vitros DT60/DT60 II 2 8.741 2.3 0.17 -10

<= -15

0 2 4 6 8 10

Concentration

Issue No: 1 Issue Date: 30/10/2019 Page 24

A ABC
MONTHLY CLINICAL CHEMISTRY LABORATORY REF. NO. 87923/A CYCLE 16 SAMPLE 10 28/10/2019

Mean for Your

Analyte Comparison Result SDI RMSDI %DEV RM%DEV TS RMTS Performance

Albumin 3.128 3.500 2.10 0.37 11.9 2.2 39 59

Alkaline Phosphatase 294.930 376.000 2.68 1.34 27.5 14.1 29 29
ALT (GPT) 159.256 165.000 0.41 0.43 3.6 3.8 110 90
Amylase, Total 310.508 234.000 -2.44 -2.24 -24.6 -21.2 28 62
AST (GOT) 164.078 199.000 2.54 2.34 21.3 20.0 31 53
Bilirubin, Direct 1.669 1.200 -1.74 -1.98 -28.1 -31.3 45 47
Bilirubin, Total 5.035 6.100 2.17 -0.52 21.1 -5.5 38 65
Calcium 12.821 14.000 1.89 0.32 9.2 1.6 44 83
Chloride 119.867 120.000 0.04 -0.50 0.1 -2.1 120 58
Cholesterol 269.125 282.000 0.84 -0.28 4.8 -1.4 79 98
CK, Total 484.921 121.000 -10.20 -8.85 -75.0 -63.9 10 19
Creatinine 4.051 4.700 1.92 0.04 16.0 0.4 39 77
Glucose 281.941 312.000 2.06 0.17 10.7 1.0 40 62
HDL-Cholesterol 111.766 132.000 1.43 0.76 18.1 9.4 54 66
Iron 229.772 328.000 7.25 Too Few 42.8 Too Few 10 Too Few
Magnesium 3.386 2.000 -3.69 Too Few -40.9 Too Few 10 Too Few
Phosphate, Inorganic 5.776 6.500 1.52 -0.27 12.5 -2.7 34 45
Potassium 5.926 5.300 -2.36 -0.76 -10.6 -3.1 20 63
Protein, Total 4.903 4.900 -0.01 0.51 -0.1 2.5 120 90
Sodium 157.188 156.300 -0.25 0.07 -0.6 0.2 120 92
Trig Total 247.165 253.000 0.31 0.92 2.4 7.4 120 94
Urea 122.745 128.000 0.58 0.34 4.3 2.6 95 69
Uric Acid (Urate) 9.258 9.200 -0.10 -0.00 -0.6 0.0 120 80

ORMSDI -0.37 ORM%DEV -3.1 ORMTS 67

ABC
END OF REPORT

Issue No: 1 Issue Date: 30/10/2019 Page 25

A